Article

RSM01, an extended half-life RSV monoclonal antibody with a high barrier to resistance

2026-02-04

Abstract excerpt

Respiratory syncytial virus (RSV) causes substantial infant morbidity and mortality, particularly in low- and middle-income countries (LMICs). RSM01 is a long-acting RSV monoclonal antibody (mAb) in development for LMICs. To date, RSM01 resistant mutants have not been able to be generated in vitro. We systematically assessed the in vitro resistance barrier of RSM01 relative to licensed RSV mAbs and the susceptibil...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fab0ad92-c6dc-595a-b093-5c806c241015
DOI: 10.64898/2026.02.04.703721

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

RSM01, an extended half-life RSV monoclonal antibody with a high barrier to resistanceDOI 10.64898/2026.02.04.703721Read

Respiratory Syncytial virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisSemantic proximity Read

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.Semantic proximity Read

Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolatesSemantic proximity Read

Complete definition of how antibodies used to prevent RSV are affected by F mutationsSemantic proximity Read

Overcoming Variants Resistance in Monoclonal Antibody for Antiviral TherapySemantic proximity Read

Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance ProfilesSemantic proximity Read

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapySemantic proximity Read

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsSemantic proximity Read

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.Semantic proximity Read

The long road to protect infants against severe RSV lower respiratory tract illnessSemantic proximity Read

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.Semantic proximity Read

Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.Semantic proximity Read